|
Corporate Collaborations (Details) (USD $)
|
1 Months Ended | 1 Months Ended | 3 Months Ended | 0 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2014
Collaborative Arrangement [Member]
|
Jun. 30, 2014
Collaborative Arrangement [Member]
Specified Development Events [Member]
|
Jun. 30, 2014
Collaborative Arrangement [Member]
Specified Regulatory Events [Member]
|
Jun. 30, 2014
Collaborative Arrangement [Member]
Specified Product Launch Events [Member]
|
Aug. 31, 2002
Daiichi Sankyo [Member]
|
Jun. 30, 2014
Daiichi Sankyo [Member]
|
Apr. 30, 2013
Daiichi Sankyo [Member]
Milestone Achievement Group One [Member]
|
Jan. 31, 2012
Daiichi Sankyo [Member]
Milestone Achievement Group One [Member]
|
Jul. 31, 2012
BerGenBio AS Worldwide License Agreement [Member]
|
Jul. 31, 2012
AstraZeneca AB Worldwide License Agreement JAK Inhibitor [Member]
|
Jun. 30, 2012
AstraZeneca AB Worldwide License Agreement JAK Inhibitor [Member]
|
Dec. 31, 2013
AstraZeneca AB Worldwide License Agreement JAK Inhibitor [Member]
Specified Development Events [Member]
|
|
| Collaborations | ||||||||||||
| Maximum amount of contingent payments receivable | $ 152,300,000 | $ 61,200,000 | $ 53,600,000 | $ 37,500,000 | ||||||||
| Upfront fee received | 1,000,000 | |||||||||||
| Revenue recognized | 1,000,000 | 5,800,000 | ||||||||||
| Collaborative payment received | 1,400,000 | 750,000 | 500,000 | |||||||||
| Cumulative amount of payments earned under collaborative arrangement | $ 7,900,000 | |||||||||||
| Period of collaboration in research phase | 3 years | |||||||||||